BIAFW (bioAffinity Technologies) Insider Ownership: 0.00 % (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIAFW bioAffinity Technologies Inc BIAFW
44 GF Score
Price $0.48
! 3 Warning Signs
View Full Analysis

What is bioAffinity Technologies Insider Ownership?

bioAffinity Technologies BIAFW +62.71% 44 Insider Ownership is 0.00 % as of Sep. 11, 2026. GuruFocus rates BIAFW with a GF Score™ of 44/100. The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, bioAffinity Technologies's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, bioAffinity Technologies's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, bioAffinity Technologies's Float Percentage Of Total Shares Outstanding is N/A.

bioAffinity Technologies Insider Ownership Historical Data

* Premium members only.

The historical data trend for bioAffinity Technologies's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

bioAffinity Technologies Insider Ownership Chart

bioAffinity Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

bioAffinity Technologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BIAFW
44GF Score
bioAffinity Technologies Inc BIAFW
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

bioAffinity Technologies Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
bioAffinity Technologies (BIAFW) has a Insider Ownership of 0.00 % as of Sep. 11, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on bioAffinity Technologies and its competitors.
Is bioAffinity Technologies' Insider Ownership too high?
bioAffinity Technologies' current Insider Ownership is 0.00 %. Overall, bioAffinity Technologies has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' Insider Ownership compare to ISPC and IVRO?
bioAffinity Technologies' Insider Ownership of 0.00 % can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Medical Diagnostics & Research company?
A good Insider Ownership depends on the Medical Diagnostics & Research industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on bioAffinity Technologies and its competitors. bioAffinity Technologies's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
bioAffinity Technologies (BIAFW) has a current Insider Ownership of 0.00 %. The current Insider Ownership is 0.00 %. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For bioAffinity Technologies (BIAFW), the current Insider Ownership is 0.00 % as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

bioAffinity Technologies Business Description

Other Exchanges BIAF:USA
Address 3300 Nacogdoches Road, Suite 216, San Antonio, TX, USA, 78217
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score

Get the complete analysis for BIAFW

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.48
Price